Journal of Bioequivalence & Bioavailability

Spectrophotometric methods for the determination of Zolpidem Tartrate in acetate buffer

3^rd World Congress Bioavailability & Bioequivalence

March 26-28, 2012 Marriott Hotel & Convention Centre, Hyderabad, India

C. N. Saketha, M. Mathrusri Annapurna and G. Aarathi

Posters: J Bioequiv Availab

Abstract:

T wo sim ple, rapid and sensitive spectrophotometric methods were developed for the determination of Zolpidem tartrate in pharmaceutical dosage forms in acetate buffer. Zolpidem tartrate is a Imidazopyridine-derivative sedative and hypnotic structurally unrelated to benzodiazepines and other sedatives and hypnotics. The hypnotic actions of Zolpidem, like benzodiazepine hypnotics, are mediated at the benzodiazepine recognition site of the GABA receptor complex. Chemically, Zolpidem is N, N, 6-trimethyl-2-p-tolylimidazo[1,2-a] pyridine-3-acetamide L-(+)-tartrate (2:1). A double beam UV-VIS spectrophotometer (UV- 1800, Shimadzu) connected to computer loaded with spectra manager software UV Probe was employed with spectral bandwidth of 1nm and wavelength accuracy of ? 0.3 nm with a pair of 10 mm matched quartz cells. Method A is a zero order and Method B is a first order (derivative) spectroscopy developed in acetate buffer. In Method A the absorption maximum was observed at 273.53 nm and in Method B the amplitude was recorded (273.53 - 318.07 nm). A graph was drawn with concentration of the drug on the x-axis and the corresponding absorbance and amplitude on the y- axis in Method A and B respectively. Beer-Lambert?s law was obeyed over the concentration range of 0.5-60 μg/ml for Method A and 5.0-60 μg/ml for Method B with correlation coefficient 0.999. The % RSD in precision and accuracy studies was found to be less than 2.0. The proposed methods were validated and can be successfully applied for the determination of Zolpidem tartrate in pharmaceutical formulations.